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The initiating somatic genetic events in chordoma development have not yet been identified. Most cytogenetically investigated
chordomas have displayed near-diploid or moderately hypodiploid karyotypes, with several numerical and structural rearrangements.
However, no consistent structural chromosome aberration has been reported. This is the first array-based study characterising DNA
copy number changes in chordoma. Array comparative genomic hybridisation (aCGH) identified copy number alterations in all
samples and imbalances affecting 5 or more out of the 21 investigated tumours were seen on all chromosomes. In general, deletions
were more common than gains and no high-level amplification was found, supporting previous findings of primarily losses of large
chromosomal regions as an important mechanism in chordoma development. Although small imbalances were commonly found, the
vast majority of these were detected in single cases; no small deletion affecting all tumours could be discerned. However, the
CDKN2A and CDKN2B loci in 9p21 were homo- or heterozygously lost in 70% of the tumours, a finding corroborated by
fluorescence in situ hybridisation, suggesting that inactivation of these genes constitute an important step in chordoma development.
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Usually located along the axial skeleton, primarily in the
sacrococcygeal and sphenooccipital regions, chordomas are
believed to be derived from remnants of the embryonal notochord
(Vujovic et al, 2006). These tumours are rare lesions accounting
for about 1–4% of all primary bone sarcomas (Mirra et al, 2002).
Several histological subtypes have been described; classical
chordoma, which is the most common entity, chondroid
chordoma, featuring regions resembling cartilage, and so-called
‘dedifferentiated’ chordoma, a rare subtype showing high-grade
features. Histologically, chordomas are composed of physalipho-
rous cells expressing a particular low molecular weight cytokeratin
pattern embedded in a mucomyxoid background (Mertens et al,
1994; Hazelbag et al, 1996; Dalpra et al, 1999; Scheil et al, 2001;
Tallini et al, 2002). Clinically, chordomas manifest as slowly
growing, locally destructive lesions with a tendency to infiltrate
into adjacent tissues. Metastases are rarely encountered but
because of difficulties in obtaining wide-margin resection of the
primary tumour, local recurrences resulting in tissue destruction
are common, eventually killing the patient.
Most cytogenetically investigated chordomas have displayed
near-diploid or moderately hypodiploid karyotypes, with several
numerical and structural rearrangements (Mitelman et al, 2007).
Recurrent chromosomal aberrations in chordomas, identified
using G-banding, metaphase comparative genomic hybridisation
(mCGH), and fluorescence in situ hybridisation (FISH), include
loss of the entire or parts of chromosomes 3, 4, 10, 13, and 18; loss
or rearrangement of 1p and 9p; and gain of chromosome 7 (Sawyer
et al, 2001; Scheil et al, 2001; Tallini et al, 2002; Kuzniacka et al,
2004; Brandal et al, 2005). However, neither by mCGH nor
cytogenetics has any consistent structural chromosome aberration
been detected. Thus, to date there is no indication that balanced or
unbalanced chromosomal exchanges leading to the creation of
fusion genes are important in chordoma development.
In the present study, biopsies from classical chordomas were
studied by bacterial artificial chromosome (BAC) array compara-
tive genomic hybridisation (aCGH) and/or FISH, with the purpose
of detecting possible cryptic chromosomal aberrations not
previously identified.
MATERIALS AND METHODS
Patients and materials
The present study included 30 tumour samples from 26 patients
(8 women and 18 men, median age 60 years). All tumours were
diagnosed as classical chordoma and located in the sacrum
(n¼20), coccyx (n¼4), or thoracic vertebrae T11–12 (n¼2).
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recurrences, and two were metastases. Clinical information is
presented in Table 1.
Chromosome banding analysis
Fresh tumour samples were processed for G-banding analysis as
previously described (Mandahl, 2001), and karyotypes were
described according to the guidelines in ISCN (1995) (Mitelman,
1995).
32k BAC microarray
Cases 1–11 were analysed using 32k tiling microarrays containing
more than 32000 partly overlapping, individual BAC clones,
generating complete coverage of the human genome. The arrays
were produced at the Swegene DNA Microarray Resource Center,
Department of Oncology, Lund University (http://swegene.onk.lu.se)
as previously described (Jo ¨nsson et al, 2007), using BAC clones
mapped to the hg17 genome build. Extraction, labelling, and
hybridisation of genomic DNA from freshly frozen tumour
biopsies, as well as pretreatment and washing of slides were
performed as described previously (Heidenblad et al, 2006). As a
control for normal copy number, a DNA pool derived from
multiple healthy male donors was used (Promega, Madison, WI,
USA).
1Mb BAC microarray
Cases 17–26, and the respective relapse in four of these tumours,
were analysed with 1Mb microarrays containing approximately
3500 BAC clones spaced at about 1Mb density over the genome.
This BAC set is distributed to academic institutions by the
Welcome Trust Sanger Institute (UK) at no cost, and information
regarding the full set is available at the Sanger Center mapping
database site, Ensembl (http://www.ensembl.org). The clones were
spotted in triplicate, and the slides used in the current study were
produced at Leiden University Medical Center, as previously
described (Knijnenburg et al, 2005). DNA isolation, labelling, and
microarray hybridisation were performed as described previously
(Rozeman et al, 2006; Knijnenburg et al, 2007).
Image and data analysis
Primary data were collected using the GenePix Pro 4.0 software
(Axon Instruments Inc., Foster City, CA, USA), and the quantified
data matrix was deposited into the web-based database BioArray
Software Environment (BASE) (Saal et al, 2002). Following
background correction using the median foreground minus the
median background signal intensity for each channel, the log2
ratios were calculated for each spot. Unreliable features marked in
the feature extraction software, and spots not showing signal-to-
noise ratios X5 for both channels, were removed. Normalisation
of data was performed using the popLowess algorithm (Staaf et al,
in press), with a window size of 1% and a segmentation constant of
5. Normalised data were smoothed using a three-probe moving
average window with adaptive thresholds (1% window size, scaling
factor 2) (Staaf et al, in press), to prevent smoothing artefacts and
allow detection of single outlier probes (subsequently removed).
Log2 ratios for each sample and platform were segmented using a
BASE implementation of CGH-Plotter (Autio et al, 2003), written
in R (http://www.r-project.org/). The segmentation constant, c, was
set to 9. Segments less than 2 probes or 500kb in size were
removed. To facilitate cross-platform comparison, segmented data
was transformed into a virtual probe set with probes spaced at
50kb throughout the entire genome by associating each platform
probe to its closest virtual probe. Copy number alterations were
determined by comparing the segmented log2 ratios to gain/loss
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Case no.
a Age/sex Site
b Size
c Treatment
d Follow-up
e Karyotype
f LSI
s s p16/cep 9
g
10P 60/F S 6 S NED 120 43,-X,der(X;1)(q22-24;p13),der(1)t(1;11)(p1?3;p1?3),der(1;22)(q10;q10),
add(3)(p12-13),der(3)t(3;12) (p25;?p11),der(5)ins(5;19)(p15;p11p12)
or der(5)ins(5;19)(p15;q11q12),der(7)t(2;7)(p15-16;q21-22) or der(7)
t(2;7)(q31-32;q21-
22),+der(7)t(7;13)(p15;?q14)t(1;13)(p22;q22),der(8)t(7;8)
(?q32;q24),?der(10)del(10)(p11) del(10)(q22),der(11)t(11;16)
(p11;q11),der(12)t(7;12)(q11;p11),?inv(12)(q13q15),-13,del(14)
(q32),-16,-17,-18
h
++/++
11P 51/M S 8 SI R 3+60+63+86+90+113,
DoD 118
42,X,-Y,der(1)t(1;3)(p31;p11-12),der(2)t(2;3)(p21;?),-3,der(3)t(2;3)
(?;p12),-4,der(5)t(5;16)(q33;?p?),der(7) t(5;7)(q33;q36),+der(8)t(1;8)
(?;q24),del(9)(p13),-10,del(11)(q13),dup(12)(q13q24),+del(12)
(q13),-16,-18, dup(18)(q?),?add(19)(q13),der(22)t(4;22)(q11;p11)/
40,X,-Y,der(1)t(1;3),der(2)t(2;3),der(2)t(2;7)(p?;?),-3, der(3)t(2;3),
der(4)t(4;7)(p?;?),der(5)t(5;16),der(6)t(6;7)(q?;?),der(7)t(5;7),
del(9),-10,del(11),dup(12),+del(12), der(13)t(8;13)
(q?;q?),-16,der(17)t(6;17)(?;q?),der(19)t(3;19),der(22)t(4;22)/
46,del(X)(q24),-Y,der(1)t(1;9) (p36;?),der(2)t(2;16)(p21;?),
der(3)t(3;14)(p21;q24)t(3;16)(q11;?)t(2;16)(?;?),der(4)t(4;13)(q3?;?),
der(5)t(5;16),der(6)t(6;8)(p23;?p21),?del(7)(q?),der(8)t(6;8)(?;p?),del
(9),del(11),der(12)t(7;12)(q?;q24)t(5;7)(q33;?), +del(12)(q13q15),
der(14)t(3;14)(q21;q24),-16,der(16)t(Y;16)(q11;p13),der(17)t
(9;17)(q?;p?),?add(17)(p11), der(19)t(X;19)(?q24;p13)
h
 +/++
12R 70/M T12 5 S, RT R 12+23, AwD 61 40-44,XY,-1,der(3)t(1;3)(q11;q11),?-4,der(9)t(9;14)(p11;p13),-22
h  +/++
13R 71/M T11 5 SI, RT R 6, DoD 50 47-48,XY,+2,inv(9)(p11q12)c,+13,-14,-16,-16,+2mar (primary tumour)
h ++/++
14P 50/M S 8 SM NED 22 43-46,XY,-3,+12,-13,add(21)(q?21),+der(?)t(?;1)(?;q21) ++/++
15R 63/M S ? SW R 157, NED 200 39-40,XY,t(1;20)(q12;q13),-3,t(6;9)(q27;q13),-10,-14,-18,-21,-22/36-
40,XY,-3,t(6;9),-10,-14,-18,der(20) t(1;20),-21,-22
 +/++
16M 32/M S ? S, RT R, M, DoD B285 33-40,X,-Y,-1,add(1)(p11)x1-2,+2,der(2;14)(q10;q10),-3,add(4)(p15),-
5,-6,ins(6;?1)(q24;q25q44),-8,-9,-10, add(11)(p15),-12,der(12)t(8;12)
(q13;q24),-13,-13,-15,add(16)(q22),-17,-18,-20,-21,-21,-22,+der(?)
t(?;13) (?;q13),+1-4r,+4mar
h
++/++
17R 59/M S ? SW NED 64 ND ND
18P 85/F S ? SI DoC 20 ND ND
19P 66/M S ? SM AwD 48 ND ND
20P 68/F S ? SW M 48, AwD 48 ND ND
21P 50/M S ? SM R 12, AwD 98 ND ND
21R SW, RT ND ND
22P
22M
52/F S ? SM M 36, AWD 48 37-40,XX,der(1)t(1;13)(p21;q33),der(2)
(2pter-2q1H6q?H2q?H6p?-6pter),der(2;17)(p10;q10),-3,-
5,del(6),del(9)(p11), der(11;14)(q10;q10),der(13),-
14,der(20)t(6;20)(p?;q10)
ND
23P 70/M S ? SI, RT LTF ND ND
24P
24R
66/M S ? SM,
SW, RT
R 36, NED 52 ND ND
25R 57/M S ? SI, RT M, LTF ND ND
26R1
26R2
42/F S ? SI, RT,
SI
R 204, AwD 210 ND ND
aCGH¼array comparative genomic hybridisation; COBRA¼combined binary ratio; F¼female; FISH¼fluorescence in situ hybridisation; M¼male.
aP¼primary tumour; R¼local recurrence; M¼metastasis.
bS¼sacrum;
C¼coccyx; T¼thoracal vertebra.
cLargest diameter in cm.
dSI¼intralesional excision; RT¼radiotherapy (postoperative); IFN¼interferon; SM¼marginal excision; SW¼wide excision; S¼surgery, not otherwise specified.
eFollow-
up in months. R¼local recurrence (time to local recurrence in months specified when known); AwD¼alive with disease; M¼metastasis (time to metastasis in months specified when known); DoD¼dead of disease; NED¼no
evidence of disease; DoC¼dead of other causes; LTF¼lost to follow-up.
fKaryotypes based on G-banding, COBRA-FISH, and aCGH results. ND¼not determined.
g(+) and ( ) indicate presence and absence, respectively, of signals
from the probe. ND¼not determined.
hKaryotypes previously published (Mertens et al, 1994; Kuzniacka et al, 2004).
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sthresholds obtained by an adaptive scaling method (Staaf et al,i n
press), using a window size of 2% and a scaling factor of 2.
Segments above gain threshold were set to 1, below loss threshold
as  1, and in-between as 0.
Microarray data are available at GEO (http://www.ncbi.nlm.nih.
gov/geo/), using the accession number GSE9023.
Fluorescence in situ hybridisation
Nine of the tumours analysed with 32k aCGH and an additional
five chordomas lacking material for aCGH (cases 12–16) were
analysed with FISH (Table 1) as described (Dahle ´n et al, 2003).
The status of the gene CDKN2A (p16) was investigated using the
commercially available LSI
s p16, a probe specific for the
centromere of chromosome 9 (cep 9), and whole-chromosome
painting probes specific for selected chromosomes (Vysis, Downers
Grove, IL, USA). Whole-chromosome painting probes were used to
discriminate tumour and normal cells. To determine presence/
absence of CDKN2A, a minimum of three tumour cells displaying
concordant LSI p16 status was required.
RESULTS
The karyotypes, based on G-banding, multicolour combined binary
ratio (COBRA)-FISH and DNA copy number profiles, are presented
in Table 1. Five out of the nine previously unpublished karyotypes
displayed a normal chromosome complement, and four showed a
near-diploid chromosome number with multiple chromosomal
imbalances. All cases, including the five tumours with normal G-
banding karyotypes, displayed genomic imbalances upon aCGH
analysis (Figure 1). Changes affecting five or more of the samples
were identified on all chromosomes (Figure 2, Table 2), and in each
case, one-third (median 0.33, range: 0.13–0.73) of the investigated
clones showed copy number alterations. There was a median of 23
deletions resulting in, on average, loss of 678Mb per tumour. The
corresponding figures for the gained regions were significantly
smaller, with a median number of 10 gained regions and a total size
of 177Mb per tumour (Po0.01, Mann–Whitney U-test). High-level
amplifications were not detected in any case, and no small deletion
was identified throughout all samples although recurrent narrow
deletions (B1Mb) were found on several chromosomes.
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Figure 1 Genomic imbalances detected in individual samples. Gains (red) and losses (green) of genomic material were detected in all samples investigated
by array comparative genomic hybridisation (aCGH). Each row corresponds to a separate sample and each column represents an individual chromosome.
The respective relapse was investigated in four cases, and samples from the same tumour showed very similar patterns of aberrations. However, although
the pattern of aberrations was almost identical, a few aberrations escaped detection in one of the samples from the same tumour. This was primarily found
for low copy number changes and can most probably be explained by normal cell contamination (See online version for colour figure.).
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Figure 2 Frequency of DNA copy number changes detected by array comparative genomic hybridisation (aCGH) in 21 chordomas. Copy number
alterations present in five or more of the samples were identified on all chromosomes. The number of deletions was larger than the number of gains, and the
size of the deleted regions was significantly larger than the gained regions. The genomic positions of the imbalances are presented in Table 2.
Table 2 aCGH findings in 21 chordomas
Regions lost or gained in X5 cases
a Most frequently affected region per chromosome
a
Cytogenetic location Start–end (Mb) Start–end (Mb) Frequency
Examples of
candidate genes
Copy number losses
1p36.33–p11.1 0.65–124.15 6.70–26.05 0.57 RUNX3
60.20–67.35 0.57
74.85–82.85 0.57
2q34–q37.3 212.15–242.81 214.95–242.81 0.33
Chromosome 3 0.04–199.45 23.05–33.35 0.71
47.10–48.65 0.71
Chromosome 4 0.01–191.25 0.01–1.25 0.43
20.20–31.50 0.43
89.70–108.25 0.43
6p21.1 41.60–43.80
7q11.22–q11.23 71.70–74.20
8p12–p11.1 36.90–45.15 37.85–42.25 0.29
9p24.3–q31.3 0.03–113.20 20.30–24.19 0.76 CDKN2A, CDKN2B
9q33.3–q34.3 125.90–138.39
Chromosome 10 0.06–135.39 11.80–12.40 0.81
11p15.5–p15.3 0.07–12.20
11p14.3–p11.2 24.75–47.95
11q12.2–q13.2 61.00–67.70
11q14.3–q25 89.85–134.43 106.95–107.70 0.38 ATM
12p11.21–p11.1 31.25–35.35
12q24.31 119.80–122.75 120.20–122.70 0.33
Chromosome 13 17.92–114.12 53.05–66.55 0.33
77.40–89.70 0.33
111.95–114.12 0.33
Chromosome 14 18.07–106.30 18.07–19.30 0.52
15q11.2 19.78–20.32
15q15.1–q21.1 38.70–42.90 40.60–41.15 0.29 TP53BP1
b
16p13.3 0.01–5.00
16p12.3–q24.3 18.15–88.70 82.40–86.10 0.52
17p13.3–p11.1 0–22.15 0–4.85 0.48 TP53
b
17q25.1–q21.3 69.00–78.39
Chromosome 18 0.02–76.10 17.40–17.95 0.48
19p13.3–p11 0.02–28.45 2.05–3.95 0.43
19q13.11–q13.43 37.60–63.77
20p11.21–q11.21 25.40–31.35 28.40–29.65 0.29
21q22.2–q22.3 41.15–46.92 43.10–46.65 0.29
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sHomozygous deletions were found on chromosomes 8, 9, and
18. The losses on chromosomes 8 and 18 were found in one case
each, and the affected regions (7.04–7.84 and 33.45–35.04Mb,
respectively) did not harbour any obvious candidate genes. The
homozygous deletions on chromosome 9 were located in the
region 20.44–27.96Mb, covering the CDKN2A locus in chromo-
somal subband 9p21.3. By aCGH, cases 4, 5, 7, 9, 11, and 19–26
showed a heterozygous deletion and cases 2, 3, and 8 displayed a
homozygous loss. These findings were confirmed by FISH in nine
cases (Figure 3; Table 1). In addition, this region was investigated
in five samples lacking material for aCGH. Two of these showed a
heterozygous deletion of LSI p16. Thus, of a total of 26 tumours
investigated, 15 (58%) displayed a heterozygous deletion of the
region covering the CDKN2A locus, and 3 (12%) showed a
homozygous deletion (Table 1).
In four of the tumours, also the respective relapse was analysed
with the 1Mb microarrays. The DNA profiles of the samples from
the same tumour were highly similar (Figure 1), and the relapses
were excluded from further analyses.
The number and the size of the aberrations were not
significantly different in the six tumours that later metastasised,
compared with the rest of the tumours. Neither was there any
chromosomal aberration that could be specifically linked to the
group of tumours that developed metastases.
DISCUSSION
In the present study, aberrant DNA copy number profiles were
detected in 21 chordomas. Primarily losses of large chromosomal
regions were found; high-level amplifications were not detected,
and there was no small deletion common to all samples. However,
frequent small deletions were found on several chromosomes.
Whether loss of these regions results in functional inactivation of
genes important in tumour development or reflects normal copy
number variation remains to be elucidated.
Overall, the results were highly consistent with previous
cytogenetic and mCGH findings, confirming that chordoma is a
genetically heterogeneous tumour lacking apparent recurrent
structural rearrangements, but demonstrating frequent imbalances
of large chromosomal regions.
Frequently deleted regions
Deletions affecting five or more samples were found on all
chromosomes, except chromosome 5, and included loss of the
entire or major parts of chromosome arm 1p and chromosomes 3,
4, 9, 10, 13, 14, 16, 18, 19, and 22 (Figure 2; Table 2).
Loss or rearrangement of 1p36 is a common finding in sporadic
chordoma, and this region has also been associated with hereditary
chordoma (Mertens et al, 1994; Dalpra et al, 1999; Miozzo et al,
2000; Riva et al, 2003; Kuzniacka et al, 2004). By loss of
heterozygosity analysis, the 1p36.31–p36.13 region was linked to
familial as well as sporadic chordoma (Miozzo et al, 2000), and the
same group later delimited the region for sporadic chordoma
development to 1p36.13 (Riva et al, 2003). In the present study, a
minimally deleted region in 1p36.31–p36.11 was found. This
region contains several genes including RUNX3, a transcription
factor, which has been shown to be frequently deleted or
transcriptionally silenced in a number of cancers, and it has been
suggested to encode an important tumour suppressor (Blyth et al,
2005). Furthermore, this gene has been shown to be implicated in
chondrocyte maturation, providing a biological link to the
development of chordoma (Soung et al, 2007).
Frequent loss of chromosome arm 9p has previously been
described in chordomas (Scheil et al, 2001; Kuzniacka et al, 2004;
Brandal et al, 2005), and particularly, the region covering the
CDKN2A (p16 and p14) and CDKN2B (p15) loci in chromosomal
band 9p21 has been shown to be deleted in many tumour types
(Gil and Peters, 2006), also in chondrosarcoma (van Beerendonk
et al, 2004). Here, we provide further evidence that loss of this
region is an important event also in chordomas, with 70% of the
Table 2 (Continued)
Regions lost or gained in X5 cases
a Most frequently affected region per chromosome
a
Cytogenetic location Start–end (Mb) Start–end (Mb) Frequency
Examples of
candidate genes
Chromosome 22 14.44–49.46 38.79–40.65 0.67 CHEK2
b
Xp22.33 0.06–2.65 0.06–2.65 0.29
Yp11.2 7.65–8.95
Yq11.22-q11.23 20.75–25.55
Copy number gains
1q21.1–q25.2 142.95–176.10
1q31.3–q43 197.45–239.20 201.20–202.35 0.38
5p15.33 0.07–3.70 TERT
5q31.1–q31.2 131.80–135.65 TGFBI
5q35.1–q35.3 170.60–180.73 171.50–180.73 0.33
6q25.3-q27 157.40–170.90 158.30–161.10 0.29
166.05–170.75 0.29 T
Chromosome 7 0.04–158.62 28.05–29.90 0.52
8q24.21–q24.22 130.55–135.15
12p13.33–p12.1 1.55–26.10 1.65–5.55 0.33 CCND2
b, FGF6
b, SOX5
b
12q13.11–q13.13 46.40–51.55 COL2A1
15q11.2 19.10–20.05
16q21–q22.2 61.30–69.45 63.65–68.50 0.29
19p13.3–p13.2 4.00–8.55
19q12–q13.43 34.40–63.77 47.70–48.30 0.33 TGFB1
b
20q11.21–q13.12 31.40–41.90 35.40–36.80 0.29 E2F1
b, SRC
20q13.33 59.20–62.43 59.90–61.60 0.29
aCGH¼array comparative genomic hybridisation.
aRegions o500kb are excluded.
bGenes located within the regions lost or gained in X five cases, but outside of the most
frequently affected region.
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stumours showing deletion of this region. Interestingly, in addition
to the three reported cases with a homozygous deletion, three more
cases in fact showed homozygous loss of the clone RP11-467K20
(cases 4, 5, and 11). This clone covers exon 1 of CDKN2A (isoform
4) as well as the entire CDKN2B, suggesting that additional
deletions affecting this region would have been identified using
arrays with even higher resolution. Noteworthy, the group of six
patients with potential homozygous loss of CDKN2A and CDKN2B
contained all five patients, investigated by aCGH, who died from
their disease. Furthermore, although no particular aberration
could be discerned distinguishing metastasising from nonmetas-
tasising tumours using aCGH, deletion of this locus was found in
all tumours that metastasised compared to two-thirds of the
nonmetastasising tumours (data not shown). Taken together, our
results are in agreement with a recent study in which immuno-
histochemic staining for the CDKN2A protein in chordoma
consistently yielded negative results (Naka et al, 2005), and
indicate that inactivation of CDKN2A may be important for
chordoma development, although not tumour-type specific.
In this context, it could be noted that loss of heterozygosity
previously has been found for the RB1 gene in chordoma
(Eisenberg et al, 1997), supporting a fundamental role for the
RB1-signalling pathway in chordoma oncogenesis. In line with
these findings, the TP53 pathway also seems to be frequently
affected in chordoma; both TP53 and TP53BP1 were recurrently
deleted. Moreover, the CHEK2 gene is located in a region on
chromosome 22, which was lost in 13 of the cases. CHEK2 is
considered a tumour suppressor and mutations of CHEK2 have
been implicated in the pathogenesis of various types of familial as
well as sporadic tumours, for example, the malignant bone tumour
osteosarcoma (Miller et al, 2002). In the minimally deleted region
on chromosome 11, which was lost in eight cases, ATM is located.
The corresponding protein is believed to be important for cell
response to DNA damage and for genome stability by regulating
signalling pathways involving CHEK2, TP53, and a variety of
additional cell cycle checkpoint proteins (Lavin and Kozlov, 2007).
Although the present study confirmed a frequent loss of
chromosomes 3, 4, 10, 13, and 18, no obvious candidate tumour
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Figure 3 DNA copy number changes in a representative chordoma. Genomic profile of case 8 analysed using 32k array comparative genomic
hybridisation (aCGH; top left). Tumour/reference log2 ratios are displayed as the moving average of three consecutive bacterial artificial chromosome
(BAC) clones, and individual chromosomes are separated by vertical bars. The profile demonstrates multiple imbalances, e.g., loss of chromosome 13 and
homozygous deletion of CDKN2A (p16) on chromosome 9 (bottom left). Fluorescence in situ hybridisation (FISH) analysis of the same case displays loss of
chromosome 13 (blue) and homozygous deletion of CDKN2A (p16) (top right). For comparison, a normal cell shows two chromosomes 13 and two normal
chromosomes 9, with centromere of chromosome 9 (cep 9) and LSI p16 indicated in green and red, respectively (bottom right) (See online version for
colour figure.).
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ssuppressors were found in the minimal deleted regions. Thus,
either these chromosomes harbour several genes of importance
for tumour development, requiring large regions to be deleted to
obtain a tumourigenic effect, or the functional inactivation is
preferentially achieved through large rearrangements. The same is
probably true for chromosomes 14, 16, and 19, which previously
have not been reported to be frequently deleted chromosomes in
chordoma.
Frequently gained regions
Generally, gains were smaller than losses and not as frequently
observed. However, as shown in previous studies, gain of
chromosome 7 is a common finding in chordomas (Sawyer et al,
2001; Scheil et al, 2001; Kuzniacka et al, 2004; Brandal et al, 2005).
The most common gain, detected in more than half of the samples,
was found in 7p15.1. This region harbours the genes CREB5, CPVL,
and CHN2, none of which has any obvious role in chordoma
development. Hence, it is likely that gain of large regions of this
chromosome is required for tumour formation.
The gene expression pattern in chordoma has in a recent study
been shown to cluster with cartilaginous tumours, particularly
chondrosarcomas (Henderson et al, 2005), although the cDNA
expression patterns clearly differ from other reported studies on
chondrosarcoma as well as other cartilaginous tumours (Rozeman
et al, 2005; Romeo et al, 2007). The study of Henderson et al
(2005), however, suggests that genes involved in cartilage
development might be of importance for chordoma oncogenesis.
In line with these findings, the locus for TGFBI on chromosome
5 was gained in five of the cases in the present study. The
corresponding protein product has been suggested to be involved
in cartilage development by stimulating the growth of prechon-
drogenic cells (Ohno et al, 2002). Similarly, SOX5 is a protein
believed to play an essential role in chondrocyte differentiation,
and five cases displayed gain of the region on chromosome arm
12p, which harbours the SOX5 gene (Lefebvre et al, 2001).
Importantly, a transcription factor known as brachyury was
demonstrated to be exclusively expressed in chordoma (Vujovic
et al, 2006), which ends the long-lasting chondroid–chordoid
dilemma (Romeo and Hogendoorn, 2006). The gene encoding
brachyury (T) is located in band 6q27, and the chromosomal
region covering this gene was gained in six of the cases.
Furthermore, none of the samples showed deletions that could
have affected this gene.
CONCLUSIONS
The DNA copy number profiles were consistent with previous
cytogenetic and mCGH findings. However, many of the DNA copy
number abnormalities identified in the present study would not
have been detected using mCGH, due to the small size of the
imbalances. In addition, even though several of the samples
analysed herein displayed a normal karyotype upon G-banding,
aCGH detected chromosomal aberrations in all cases. This is
most likely explained by a growth advantage in vitro for
normal cell populations. Thus, although it has been suggested
that chromosomal abnormalities in chordomas represent late
events in tumour progression (Sawyer et al, 2001; Sandberg and
Bridge, 2003), the results in the current study indicate that all
chordomas harbour chromosomal imbalances.
In agreement with previous studies (Scheil et al, 2001), recurrent
tumours did not show more chromosomal abnormalities than the
respective primary lesions; in fact, the DNA profiles were almost
identical. Neither did the DNA copy number pattern differ between
tumours that developed metastases and the nonmetastasising
tumours. Thus, although the number of cases studied was low, there
was no obvious correlation between the number, size, or location of
the aberrations detected and the clinicopathologic features.
We were not able to distinguish any chordoma-specific markers
useful for diagnosis. In fact, many of the findings in this study, such
as loss of 1p36, 9p, and 10p and gain of 7p are abnormalities
previously detected in other bone tumours, for example, chondro-
sarcomas (Bovee et al, 2001; Sandberg and Bridge, 2003). None-
theless, the characterisation of DNA copy numbers in chordoma
provides important information about the genetic basis of
chordoma development, and clinically important aberrations will
hopefully emerge from future studies when the copy number
alterations can be associated with gene expression profiles.
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